Gregg Stone announced as co-principal investigator of ALIVE trial of Revivent TC system for heart failure

BioVentrix BioVentrix has announced that Gregg Stone (Mount Sinai Health System, New York, USA) has signed on as principal investigator of the ALIVE trial of the Revivent TC transcatheter ventricular enhancement system. The system is a hybrid, closed-chest transcatheter procedure designed to treat patients with ischaemic cardiomyopathy by reshaping and restoring the [...]

2020-02-27T13:13:14+00:00February 27th, 2020|Tags: , , |

FDA Breakthrough Device Designation granted to Revivent TC transcatheter ventricular enhancement system

Revivent TC The FDA has granted Breakthrough Device Designation status for its Revivent TC transcatheter ventricular enhancement system (BioVentrix) for heart failure. A press release reports that the less invasive ventricular enhancement (LIVE) procedures uses Revivent TC System to exclude scar tissue on the left ventricle that has resulted from a myocardial [...]

2019-11-20T13:02:50+00:00November 20th, 2019|Tags: , , |
Go to Top